Backed By Multiple Bullish Technicals, Biotech Breakout Idea (Nasdaq: ANIX) Is On Watch Now

A new multi-month high? A double-digit intraday surge? Backed By Multiple Bullish Technicals, Biotech Breakout Idea (Nasdaq: ANIX) Is On Watch Now January 16th Dear Reader, You're officially on the clock to pull up: *Anixa Biosciences, Inc. (ANIX)* Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's treatment portfolio includes a novel treatment being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a treatment to prevent ovarian cancer. And based on these glaring potential catalysts, ANIX could be set to take the breakout stage. Check them out: #1. Bullish Technical Indicators (At Least 10 Triggered This Moment). #2. Game-Changing News Comes In The Form Of Positive Phase 1 Study Data. #3. Analyst Targets Suggest Triple-Digit Upside Potential From Current Levels. But more on those in a second... Anixa Snapshot Clinical-stage company developing first-in-class products to treat & prevent cancer. Anixa Biosciences, Inc. is developing therapies and treatments that are focused on critical unmet needs in oncology. Anixa’s programs are using the body’s immune system to take multiple approaches in fighting cancer—CAR-T cell therapy to treat cancer and treatments to prevent cancer. Therapeutics CAR-T Anixa is developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer. Treatments Breast Cancer Treatments The company is developing a revolutionary treatment technology focused on preventing breast cancer, specifically triple negative breast cancer, the most lethal form of the disease. Ovarian Cancer Treatment Using a similar mechanism of action as our breast cancer treatment technology, the company is developing a treatment to prevent the occurrence of ovarian cancer. Today's ANIX Focus: Pre-Clinical Studies Treatment Prevents Breast Cancer Phase 1 Trial - Conducted by Cleveland Clinic, fund-ed by U.S. Department of Defense (DOD) An open-label Phase 1 dose-escalation trial Design: Participants will receive three treatments, each two weeks apart, and will be closely monitored for side effects and immune response Phase 1a (in progress): - 18-24 Patients who have been treated for TNBC - Safety will be monitored - Immune Response will be monitored - Maximum Tolerated Dose (“MTD”) determined Phase 1b (enrollment open): - Healthy women w/mutations - Chosen to undergo prophylactic mastectomy - Treatment before surgery and evaluate immune response and resected tissue - Unique opp. to garner supplemental data after studying breast tissue to determine if T cells are surveilling the tissue without any visible cancer tumors Phase 1c (enrollment open): - Additional cohort combining treatment with Keytruda - Patients treated for TNBC - Combine Keytruda w/ treatment to evaluate if there is synergy Breast Cancer Treatment: A Significant Market Opp. Successive to appropriate clinical trials, a prophylactic (preventative) treatment may be eventually administered to the total eligible population. Multi-Bn Dollar Market opp. 1) National Cancer Institute If this treatment works as the company hopes and expects, every woman in the world may be eligible! Anixa's Product Pipeline Sources: [Company Website.]( [Company Presentation.]( ----- Though that fills you in on the incredible company moves that ANIX is up to currently, it doesn't get to the heart of what we need to focus on right this second. *Here Are The Most Pressing Potential Catalysts ANIX Is Working With... #1. Bullish Technical Indicators (At Least 10 Triggered This Moment). At close on Friday, [Barchart]( was reporting ANIX to have a multitude of bullish technical indicators across the short, medium, and long term. Here's a quick list: Short Term Indicators - 20 Day Moving Average - 20 - 50 Day MACD Oscillator - 20 - 100 Day MACD Oscillator - 20 - 200 Day MACD Oscillator Medium Term Indicators - 50 Day Moving Average - 50 - 100 Day MACD Oscillator - 50 - 150 Day MACD Oscillator Long Term Indicators - 100 Day Moving Average - 150 Day Moving Average - 200 Day Moving Average Not only those, but Barchart's composite "Trend Seeker" indicator is triggered, too. #2. Game-Changing News Comes In The Form Of Positive Phase 1 Study Data. Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences stated: "The data from our Phase 1 trial to date has exceeded our expectations, and we are pleased with our progress. This treatment is designed to direct the immune system to destroy TNBC cancer cells through a mechanism that has never previously been utilized for cancer treatment development." #3. Analyst Targets Suggest Triple-Digit Upside Potential From Current Levels. Last, but no least, at least 2 different analysts have painted rosy targets on ANIX. Take a look at what [MarketBeat]( has to share: From Friday's closing valuation, these two targets represent over a 100+% potential upside! Could it be time to stop sleeping on Anixa Biosciences, Inc. (ANIX)? Time is officially ticking to get ANIX on radar now. When updates pop up, I'll have them out to you quickly this week. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 1/15/24 and ending on 1/16/24 to publicly disseminate information about (ANIX) via Website, Email and SMS. SWN Media LLC was paid twenty thousand USD via bank wire transfer. We own zero shares of (ANIX). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Sica Media LLC, TD Media LLC has been hired for a period beginning on 1/15/2024 and ending on 1/15/2024 to publicly disseminate information about (ANIX:US) via digital communications. We have been paid forty thousand dollars USD. We own zero shares of (ANIX:US). Pursuant to an agreement between TD Media LLC and Sica Media LLC, TD Media LLC has been hired for a period beginning on 1/16/2024 and ending on 1/16/2024 to publicly disseminate information about (ANIX:US) via digital communications. We have been paid sixteen thousand dollars USD. We own zero shares of (ANIX:US). To date we have been paid fifty-six thousand dollars USD to disseminate information about (ANIX:US) via digital communications. We own zero shares of (ANIX:US). [( Fierce | 4834 NW 2nd Ave, Unit #388, Boca Raton, FL 33431 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net